Success Metrics

Active Trials

3(100%)

Phase Distribution

Ph phase_2

33%

Ph phase_1

33%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Detailed Status

Recruiting2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

Phase 31 (33.3%)

Trials by Status

active_not_recruiting133%

recruiting267%

Recent Activity

3 active trials

Showing 3 of 3

active_not_recruitingphase_2

Evolutionary Therapy for Rhabdomyosarcoma

NCT04388839

recruitingphase_1

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

NCT04625907

recruitingphase_3

Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor

NCT02639650

Clinical Trials (3)

Showing 3 of 3 trials

NCT04388839Phase 2

Evolutionary Therapy for Rhabdomyosarcoma

Active Not Recruiting

NCT04625907Phase 1

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Recruiting

NCT02639650Phase 3

Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor

Recruiting

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3